Teva Pharma (TEVA) Tops Q4 EPS by 2c, provides guidance

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.71, $0.02 better than the analyst estimate of $0.69. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.1 billion.

GUIDANCE:

Teva Pharma sees FY2025 EPS of $2.35-$2.65, versus the consensus of $2.78. Teva Pharma sees FY2025 revenue of $16.8-17.4 billion, versus the consensus of $17.087 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Goldman Sachs (GS) Reiterated at Market Perform by Citizens on Constructive Backdrop
• OptimizeRX (OPRX) Reiterated at Market Outperform by Citizens Before Annual Forum
• Jefferies Financial Group (JEF) Misses Q2 EPS by 22c